Web-based questionnaire survey for the consciousness of patients and doctors about the discontinuation of dyslipidemia treatment

JRCT ID: jRCT1080224546

Registered date:04/02/2019

Basic Information

• Recruitment status: completed
• Health condition(s) or Problem(s) studied: Dyslipidemia
• Date of first enrollment: 27/02/2019
• Target sample size: 2051
• Countries of recruitment: Japan
• Study type: Observational

Intervention(s)

investigational material(s)
Generic name etc : Dyslipidemia Therapeutic Agent
INN of investigational material : -
Therapeutic category code : 218 Agents for hyperlipidemias
Dosage and Administration for Investigational material : Dosage regimen for each drug for treating dyslipidemia is used as described in the package insert.

control material(s)
Generic name etc : -
INN of investigational material : -
Therapeutic category code : --- Other
Dosage and Administration for Investigational material : -

Outcome(s)

Primary Outcome

other
[Survey in physician]
Characteristics (Including screening item): 10 questions
[Survey in patient]
Characteristics (Including screening item): 6 questions

Timeframe: 12 days
other
[Survey in physician]
Measurement item: 20 questions
[Survey in patient]
Measurement item:30 questions

Timeframe: 12 days

Secondary Outcome

other
-

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

[Physician survey]
1.Treat 50 patients with dyslipidemia per month
2.Finish a doctor-in-training

[Patient survey]
1.Over 20 years old dyslipidemia patients
2.Have visited a medical institution for the treatment of dyslipidemia within the past 1 year
3.Have been prescribed oral dyslipidemia medications
4.Not a healthcare provider

• Exclude criteria: -

Related Information

• Primary Sponsor: Takeda Pharmaceutical Company Limited
• Secondary Sponsor: -
• Source(s) of Monetary Support: -
• Secondary ID(s): JapicCTI-194615